COMMUNIQUÉS West-GlobeNewswire

Beacon Behavioral Partners Welcomes Novus Neurology and SunCoast Psychiatry
24/03/2026
Partnerships Expand Access to Advanced Neurological and Psychiatric Care in Florida and Alabama BATON ROUGE, La., March 24, 2026 (GLOBE NEWSWIRE) -- Beacon Behavioral Partners (BBP), a growing national network of [...]
Press Release Biocartis NV: Biocartis to Collaborate with Medical College of Wisconsin on Breast Cancer Gene Signatures
24/03/2026
PRESS RELEASE - 03/24/2026, 08:00 EDT Biocartis to Collaborate with Medical College of Wisconsin on Breast Cancer Gene Signatures Itasca, IL, US, 24 March 2026 – Today, Biocartis announced that it has entered into a [...]
Immutrin raises £65 million ($87 million) Series A to develop next generation antibody therapy for ATTR amyloidosis
24/03/2026
Oversubscribed financing led by Frazier Life Sciences with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge Innovation Capital and Cambridge Enterprise Ventures Proceeds will [...]
IMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
24/03/2026
LAWRENCEVILLE, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- IMUNON , Inc. (Nasdaq: IMNN) , a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that the Company will host a [...]
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
24/03/2026
Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of action THE WOODLANDS, Texas, March 24, 2026 [...]
Sapu Nano to Launch Deciparticle™ Platform and Present Clinical Pipeline at BIO-Europe Spring 2026
24/03/2026
AGOURA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), a leader in RNA-based therapeutics, announced today that its subsidiary [...]
Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer
24/03/2026
RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic [...]
Addgene and Plasmidsaurus Announce Strategic Partnership to Scale Sequencing for Leading Plasmid Repository
24/03/2026
Strategic partnership to ensure delivery of scalable, cost-effective, and reliable plasmid sequencing as Addgene’s repository expands WATERTOWN, Mass. and SAN FRANCISCO, March 24, 2026 (GLOBE NEWSWIRE) -- Addgene , an [...]
Callio Therapeutics Doses First Patient in Phase I Clinical Trial of Dual-Payload ADC CLIO-8221 in Advanced HER2-Expressing Solid Tumors
24/03/2026
Callio Therapeutics is actively developing a pipeline of promising dual-payload ADCs featuring rationally designed payload combinations for hard-to-treat tumors CLIO-8221 is the first program from Callio Therapeutics [...]
Applied StemCell and Cellipont Bioservices Partner to Offer a Seamless Path for iPSC-Derived Cell Therapy Development
24/03/2026
MILPITAS, Calif. and THE WOODLANDS, Texas, March 24, 2026 (GLOBE NEWSWIRE) -- Applied StemCell, Inc. (“ASC”), a genome engineering company with deep expertise in induced pluripotent stem cell (iPSC) technology and [...]
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
24/03/2026
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, March 24, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and [...]
Calidi Biotherapeutics Announces Partnership with Avance Clinical to Facilitate Australian Regulatory Approval and Accelerate Initiation of CLD-401 Clinical Trials
24/03/2026
SAN DIEGO, March 24, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today [...]
Leapfrog Bio Appoints Alan Ashworth, Ph.D., FRS, to Chair Company’s Scientific Advisory Board
24/03/2026
-- Dr. Ashworth Brings Decades of Scientific and Clinical Experience Translating Synthetic Lethality Discoveries into Precision Cancer Therapies -- SOUTH SAN FRANCISCO, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- [...]
LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
24/03/2026
Launched VIZZ ® (aceclidine ophthalmic solution) 1.44% for the treatment of presbyopia in October 2025 and generated net product revenues of $1.6 million in the first quarter of launch On pace for over 45,000 paid [...]
Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference
24/03/2026
SEATTLE, March 24, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating [...]
Hyperion DeFi Enters HAUS Agreement with Silhouette
24/03/2026
Latest DeFi Monetization Agreement Generates Scalable Revenues and Ecosystem Rewards in Partnership with Private Trading Infrastructure on Hyperliquid LAGUNA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Hyperion [...]
Ocugen Announces Topline 12-month Data from Phase 2 ArMaDa Clinical Trial Evaluating OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
24/03/2026
Optimal dose intended for Phase 3 demonstrates statistically significant reduction in lesion growth (31%) versus control at 12 months (p< 0.05) Potential 2X treatment benefit compared to 15% and 22% reductions [...]
Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026
24/03/2026
WAYNE, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (“Palvella” or “the Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel [...]
Bavarian Nordic A/S – Notice Convening Annual General Meeting
24/03/2026
COPENHAGEN, Denmark, 24 March 2026 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on Tuesday, 21 April [...]

Pages

Other news

Test 2

22/10/2026

Lorem ipsum

Test 1

22/10/2026

Lorem upsum